CLRB
NASDAQCellectar Biosciences Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.54-0.10 (-3.98%)
03:15 PM06:30 PM
News · 26 weeks33-23%
2025-12-142026-06-07
Mix2590d
- SEC Filings13(52%)
- Other5(20%)
- Analyst2(8%)
- Offering2(8%)
- Insider2(8%)
- Earnings1(4%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Cellectar Biosciences Inc.SCHEDULE 13G - Cellectar Biosciences, Inc. (0001279704) (Subject)
- SECSEC Form 424B3 filed by Cellectar Biosciences Inc.424B3 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form EFFECT filed by Cellectar Biosciences Inc.EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual MeetingApproximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase 3 Confirmatory Clinical Trial in 4Q26 FLORHAM PARK, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that efficacy results from a subset of patients treated with iopofosine I 131 immediately post-Bruton Tyrosine Kinase inhibitor (BTKi) therapy in the Company's Phase 2 CLOVER WaM clinical trial of iopofosine I 131 to tre
- SECAmendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.S-1/A - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form DEFA14A filed by Cellectar Biosciences Inc.DEFA14A - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form DEF 14A filed by Cellectar Biosciences Inc.DEF 14A - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form S-1 filed by Cellectar Biosciences Inc.S-1 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form PRE 14A filed by Cellectar Biosciences Inc.PRE 14A - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Leadership Update8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- ANALYSTLadenburg Thalmann initiated coverage on Cellectar Biosciences with a new price targetLadenburg Thalmann initiated coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $10.00
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesAnnounced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026 Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy Data Expected Mid-year 2026 Company to Hold Webcast and Conference Call at 8:3
- SECSEC Form 10-Q filed by Cellectar Biosciences Inc.10-Q - Cellectar Biosciences, Inc. (0001279704) (Filer)
- INSIDERChief Operating Officer Longcor Jarrod bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 74% to 20,451 units (SEC Form 4)4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- INSIDERChief Executive Officer Caruso James V bought $24,998 worth of shares (8,680 units at $2.88), increasing direct ownership by 75% to 20,318 units (SEC Form 4)4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)
- PRCellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026FLORHAM PARK, N.J., May 11, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2026, and provide a corporate update on May 14, 2026, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Thursday, May 14, 2026Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:Webcast:63374Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website. About Cellectar Bios
- SECCellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Cellectar Biosciences, Inc. (0001279704) (Filer)
- SECSEC Form 424B5 filed by Cellectar Biosciences Inc.424B5 - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia83.6% ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 months FDA-requested dataset with ≥12-month follow-up on all patients strengthens regulatory positioning for accelerated approval and supports initiation of confirmatory trial in 4Q26 Compelling efficacy observed in post-BTKi patients, including ~64% MRR and durable responses exceeding 18 months Recently Announced Oversubscribed Financing of up to $140 Million with Leading Healthcare Institutional Investors Supports Confirmatory Study and NDA Filing for Accelerated Approval of Iopofosine I 131 in Waldenström Macroglobulinemia with the FDA FLORHAM PARK, N.J., May 05, 2026 (GLOBE NE
- PRCellectar Biosciences Announces Oversubscribed Financing Up to $140 MillionOversubscribed Financing Led by Nantahala Capital with Participation from Balyasny Asset Management, Caligan Partners, Janus Henderson Investors, SilverArc Capital Management, Stonepine Capital Management, Empery Asset Management LP, StemPoint Capital LP and other Dedicated Healthcare Funds along with Members of the Executive Management Team Financing of up to $140 Million Supports Confirmatory Study and NDA Filing for Accelerated Approval of Iopofosine I 131 in Waldenström Macroglobulinemia with the FDA Andrew Gu of Nantahala Capital Management, LLC to Join the Company's Board of Directors Upon Closing FLORHAM PARK, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (
- SECAmendment: SEC Form 10-K/A filed by Cellectar Biosciences Inc.10-K/A - Cellectar Biosciences, Inc. (0001279704) (Filer)
- PRCellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026FLORHAM PARK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance of an abstract for poster presentation at the American Society of Clinical Oncology Annual Meeting taking place May 29 - June 2 in Chicago, Illinois. "We are pleased to share data from this important subset of r/r WM patients for whom there are no approved therapies and remaining options are restricted to salvage therapies which provide limited benefit. It is important to note that approximately 60% of drugs used for all WM patients are
- PRCellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)FLORHAM PARK, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the first patient has been enrolled in the Phase 1b trial of CLR 121125 (CLR 125) for the potential treatment of triple negative breast cancer (TNBC). CLR 125 is Cellectar's proprietary Auger-emitting radioconjugate incorporating iodine-125 to achieve intracellular delivery and direct DNA-level damage in tumor cells. The molecular structure of CLR 125 is identical to that of iopofosine I 131 (CLR 131) and the demonstrated clinical activity, safety
- ANALYSTCellectar Biosciences upgraded by Maxim Group with a new price targetMaxim Group upgraded Cellectar Biosciences from Hold to Buy and set a new price target of $10.00
CLRB FAQ
6 questionsWhat does Cellectar Biosciences Inc. do?
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic...Where does CLRB stock trade?
Cellectar Biosciences Inc. (CLRB) is listed on NASDAQ.What sector and industry is CLRB in?
Cellectar Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CLRB?
Cellectar Biosciences Inc. has had 3 recent analyst actions on file. The most recent action was from Ladenburg Thalmann: Buy with a $1000.00 price target on 2026-05-15. Recent price targets range from $1000.00 to $1300.00.What companies are similar to CLRB?
Notable peers in the same industry include SELB (Selecta Biosciences Inc.), ATNM (Actinium Pharmaceuticals Inc. (Delaware)), XBIO (Xenetic Biosciences Inc.). Compare CLRB side-by-side with any of them on Quantisnow.How can I track CLRB on Quantisnow?
Quantisnow aggregates Cellectar Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLRB to receive live email and push alerts on every new disclosure.